MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517075243 A) filed by Monte Rosa Therapeutics Ag, Basel, Switzerland, on Aug. 7, for 'targeted degradation of vav1.'
Inventor(s) include Mcallister, Laura Ann; Liardo, Elisa; Ritzen, Andreas; Oleinikovas, Vladimiras; Cabre, Xavier Lucas; Fasching, Bernhard; Bizzini, Lorenzo Delarue; and Lesieur, Mathieu.
The application for the patent was published on Sept. 12, under issue no. 37/2025.
According to the abstract released by the Intellectual Property India: "This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder."
The patent application was internationally filed on Jan. 08, 2024, under International application No.PCT/US2024/010733.
Disclaimer: Curated by HT Syndication.
